Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$172.06
Market cap
$304.05B
P/E Ratio
59.74
Dividend/share
$6.29
EPS
$2.88
Enterprise value
$367.88B
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate
Highlights
ABBV's gross profit is up by 8% since the previous quarter and by 2.9% year-on-year
The gross margin has grown by 7% from the previous quarter and by 2.1% YoY
ABBV's P/E is 78% above its 5-year quarterly average of 33.6
AbbVie's equity has plunged by 50% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of ABBV
Market
Valuations
Earnings
Shares outstanding
1.77B
Market cap
$304.05B
Enterprise value
$367.88B
Price to earnings (P/E)
59.74
Price to book (P/B)
50.38
Price to sales (P/S)
5.48
EV/EBIT
40.36
EV/EBITDA
21.05
EV/Sales
6.62
Revenue
$55.53B
Gross profit
$37.32B
Net income
$5.12B
EBIT
$9.11B
EBITDA
$17.47B
Free cash flow
$15.62B
Per share
Balance sheet
Liquidity
EPS
$2.88
EPS diluted
$2.88
Free cash flow per share
$8.83
Book value per share
$3.41
Revenue per share
$31.39
TBVPS
$23.45
Total assets
$143.42B
Total liabilities
$137.35B
Debt
$71.08B
Equity
$6.03B
Working capital
-$15.28B
Debt to equity
11.78
Current ratio
0.65
Quick ratio
0.44
Net debt/EBITDA
3.65
Margins
Efficiency
Dividend
EBITDA margin
31.5%
Gross margin
67.2%
Net margin
9.2%
Operating margin
24.9%
Return on assets
3.6%
Return on equity
65.7%
Return on invested capital
14.6%
Return on capital employed
9.1%
Return on sales
16.4%
Dividend yield
3.66%
DPS
$6.29
Payout ratio
218.4%
ABBV stock price
How has the AbbVie stock price performed over time
Intraday
-0.32%
1 week
0.41%
1 month
-2%
1 year
4.03%
YTD
-3.17%
QTD
-3.17%
Financial performance
How have AbbVie's revenue and profit performed over time
Revenue
$55.53B
Gross profit
$37.32B
Operating income
$13.82B
Net income
$5.12B
Gross margin
67.2%
Net margin
9.2%
The net margin has declined by 22% year-on-year and by 5% since the previous quarter
The company's net income fell by 21% YoY and by 4.1% QoQ
The operating income has grown by 13% from the previous quarter but it has contracted by 8% YoY
The operating margin rose by 12% since the previous quarter but it has declined by 9% year-on-year
Growth
What is AbbVie's growth rate over time
Valuation
What is AbbVie stock price valuation
P/E
59.74
P/B
50.38
P/S
5.48
EV/EBIT
40.36
EV/EBITDA
21.05
EV/Sales
6.62
ABBV's P/E is 78% above its 5-year quarterly average of 33.6
The EPS has contracted by 21% YoY and by 4% from the previous quarter
ABBV's price to book (P/B) is 132% higher than its 5-year quarterly average of 21.8 and 20% higher than its last 4 quarters average of 42.3
AbbVie's equity has plunged by 50% YoY and by 11% from the previous quarter
ABBV's P/S is 22% above its 5-year quarterly average of 4.5 but 3.5% below its last 4 quarters average of 5.7
Efficiency
How efficient is AbbVie business performance
The ROE has grown by 40% YoY and by 15% from the previous quarter
AbbVie's return on assets has decreased by 25% YoY and by 5% QoQ
AbbVie's ROIC has decreased by 8% YoY but it has increased by 2.1% from the previous quarter
The ROS has contracted by 7% YoY but it has grown by 2.5% from the previous quarter
Dividends
What is ABBV's dividend history
DPS
$6.29
Dividend yield
3.66%
Payout ratio
218.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did AbbVie financials performed over time
AbbVie's total assets is 4.4% higher than its total liabilities
The quick ratio has contracted by 38% YoY and by 25% from the previous quarter
ABBV's current ratio is down by 32% year-on-year and by 20% since the previous quarter
The company's debt to equity has surged by 135% YoY and by 13% QoQ
AbbVie's equity has plunged by 50% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.